## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to methods, results, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors compiled a new benchmark dataset annotating binding amino acids within intrinsically disordered regions (IDRs) and used it to perform the first comparative assessment of 14 methods predicting disordered binding residues. They report that current methods perform poorly at identifying binding IDRs among disordered residues, but several tools outperform random expectations for binding residue prediction. They identify at least one relatively accurate predictor for disordered protein-binding and one for disordered nucleic acid-binding residues. Cross-prediction analysis indicates most methods are ligand-type-agnostic, with only two predictors for each ligand class considered ligand-type-specific. The authors discuss future directions for improving accuracy, reducing cross-predictions, and expanding ligand coverage.
- **Visible evidence base** Abstract text only; no dataset details, method descriptions, performance metrics, statistical analyses, or figures/tables provided
- **Missing materials affecting confidence** Full manuscript, benchmark dataset construction details, method selection criteria, evaluation protocols, performance numbers, statistical significance tests, cross-prediction analysis methodology, and any supplementary data

## Reviewer
- **Overall assessment** The abstract presents a potentially valuable benchmarking effort addressing an underexplored granularity of prediction in intrinsically disordered regions. The claim of a first-of-its-kind assessment is plausible given the focus on binding residue-level annotations rather than IDR-level annotations. However, the abstract alone provides insufficient evidence to evaluate the rigor of the benchmark construction, the fairness of method comparisons, or the statistical validity of the conclusions. The findings, as stated, are qualitative and lack quantitative support. The identification of ligand-type-specific predictors is interesting but requires verification of the criteria used to define specificity. The manuscript could make a useful contribution to the protein prediction community if the full evidence supports the claims, but the current abstract does not establish the case.
- **Who would be interested in the results, and why** Computational biologists and bioinformaticians developing or using predictors for intrinsically disordered regions and binding site annotation. Researchers studying protein-protein and protein-nucleic acid interactions, particularly those focused on disordered regions, would benefit from guidance on method selection. Method developers in the field of disordered protein prediction would find the comparative assessment and identified limitations useful for improving future tools.
- **Major strengths** The focus on binding residue-level annotations within IDRs addresses a gap in existing benchmarking efforts, which typically operate at the IDR level. The inclusion of ligand type-specific analysis (protein versus nucleic acid) adds practical relevance. The use of a new benchmark dataset with low-similarity test proteins suggests an attempt to reduce training bias. The identification of at least one relatively accurate tool for each ligand class provides actionable guidance for users.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality is potentially high given the claimed first assessment at residue level within IDRs, but this cannot be fully verified from the abstract. Scientific importance is moderate to high for the specialized field of disordered protein prediction, though the broader impact may be limited to computational biology. Interdisciplinary readership is narrow, primarily attracting bioinformaticians and structural biologists. Technical soundness cannot be assessed from the abstract alone, as no methodological details or quantitative results are provided. Readability for nonspecialists is adequate, with clear language and logical flow, though some terms such as "ligand-type-agnostic" may require definition for a general audience.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a potentially valuable study, but the absence of quantitative results and methodological details prevents verification of the core claims. A supportive posture would require access to the full manuscript demonstrating rigorous benchmark construction, appropriate statistical analysis, and clear evidence for the ligand-type-specificity claims.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that "current methods struggle to accurately predict binding IDRs among disordered residues; however, better-than-random tools predict disordered binding residues significantly better than binding IDRs."
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract provides no quantitative metrics, such as area under the receiver operating characteristic curve, precision-recall values, or Matthews correlation coefficients, to support the comparative claims. The terms "struggle" and "significantly better" are used without statistical backing or effect sizes.
- **Why it matters** Without numerical evidence and statistical tests, the reader cannot evaluate the magnitude of the reported differences or determine whether the conclusions are robust. The claim of "significantly better" requires formal hypothesis testing, which is not described.
- **Resolution test** Provide performance metrics for all 14 methods on the benchmark dataset, including confidence intervals and statistical significance tests comparing binding residue prediction to binding IDR prediction. Report effect sizes to substantiate the qualitative descriptors.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Methodological transparency
- **Claim pointer** The authors state that they "compiled a new benchmark dataset that annotates binding AA in IDRs" and "evaluated a representative collection of 14 methods."
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract does not describe how the benchmark dataset was constructed, including the source of annotations, the criteria for defining binding residues, the number of proteins used, or the sequence similarity threshold. Similarly, the selection criteria for the 14 methods are not stated, nor is it clear whether these methods were used with their default parameters or retrained.
- **Why it matters** Benchmark quality and method selection directly affect the validity of comparative conclusions. Without details on annotation reliability, dataset size, and method configuration, the results cannot be reproduced or assessed for fairness.
- **Resolution test** Describe the benchmark construction process, including annotation sources, curation steps, and similarity filtering. Specify the version and parameters for each of the 14 methods, and justify their selection as representative.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim substantiation
- **Claim pointer** The authors claim that "only two predictors of the nucleic acid-binding IDRs and two predictors of the protein-binding IDRs can be considered as ligand-type-specific."
- **Evidence pointer** Abstract only; location not provided
- **Concern** The criteria for defining "ligand-type-specific" are not provided. It is unclear whether this classification is based on statistical comparison of cross-prediction rates, a threshold on performance differences, or some other metric. The abstract also does not specify which methods meet this criterion.
- **Why it matters** The ligand-type-specificity claim is a key finding with practical implications for method selection. Without a clear operational definition and supporting data, the claim is not verifiable and could mislead users.
- **Resolution test** Define the quantitative criterion for ligand-type specificity, such as a significant difference in performance between protein-binding and nucleic acid-binding prediction tasks. Report the specific methods that meet this criterion and the associated statistics.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract terminology
- **Evidence pointer** Abstract text
- **Issue** The term "ligand-type-agnostic" is used without definition, which may confuse readers unfamiliar with the prediction literature.
- **Required correction** Define the term in the abstract or replace it with a more explicit phrase, such as "methods that do not distinguish between protein and nucleic acid binding partners."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Scope justification
- **Affected element** Method selection
- **Evidence pointer** Abstract text
- **Issue** The abstract states that 14 methods were evaluated as "representative," but no rationale is given for why these specific methods were chosen or how they represent the broader field.
- **Required correction** Briefly justify the selection criteria, such as popularity, availability, or diversity of approaches, in the abstract or methods section.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Future directions
- **Evidence pointer** Abstract text
- **Issue** The abstract mentions "several potential future directions" but does not enumerate them, leaving the reader without a sense of the proposed next steps.
- **Required correction** List the key future directions explicitly, even in abbreviated form, to give the abstract more substance.

## Risk / unsupported claims
- The claim that this is a "first-of-its-kind assessment" of disordered binding residue predictions is not verifiable from the abstract alone, as no literature comparison is provided.
- The claim that "better-than-random tools predict disordered binding residues significantly better than binding IDRs" is unsupported without statistical evidence.
- The identification of "at least one relatively accurate tool" for each ligand class is unsubstantiated without performance numbers or method names.
- The classification of methods as "ligand-type-agnostic" or "ligand-type-specific" is not supported by any defined criteria or data.
- The statement that "current methods struggle" is a qualitative judgment that cannot be evaluated without quantitative benchmarks.